Krystal Biotech

Krystal Biotech

Biotechnology
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.

$10.4B

Market Cap • 9/11/2026

2015

(11 years)

Founded

2017

(9 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

7,6

P/S

23,5

P/EBITDA

50,7

P/OCF

38,1

P/FCF

40,2

P/E

43,9

BVPS

44,8

EPS

8

Market Cap

Market Cap

10,4B

EV

9,5B

EV/Revenue

21,6

EV/EBITDA

46,7

EV/EBIT

48,2

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-0,2%

Total Yield

-0,2%

Payout

0%

Retained Earnings

134,9M

Profitability

Gross Margin

94,6%

EBITDA Margin

46,4%

EBIT Margin

44,9%

Net Margin

54,8%

D&A/EBITDA

0%

R&D/Revenue

13,4%

Capex/Revenue

3,3%

Capex/D&A

218,4%

Capex/OCF

5,3%

SBC/OCF

20,1%

% PPE

10,7%

% Goodwill

0%

ROE

20,1%

ROIC

39,8%

Leverage

N.D./EBITDA

Debt/Equity

0%

Current Ratio

8,3

Quick Ratio

7,7

Interest Coverage

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium